SG11201900991UA - Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof - Google Patents
Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereofInfo
- Publication number
- SG11201900991UA SG11201900991UA SG11201900991UA SG11201900991UA SG11201900991UA SG 11201900991U A SG11201900991U A SG 11201900991UA SG 11201900991U A SG11201900991U A SG 11201900991UA SG 11201900991U A SG11201900991U A SG 11201900991UA SG 11201900991U A SG11201900991U A SG 11201900991UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- synthesis
- acceptable salts
- california
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/1616—Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
- C07D301/03—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
- C07D301/12—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with hydrogen peroxide or inorganic peroxides or peracids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/70—Complexes comprising metals of Group VII (VIIB) as the central metal
- B01J2531/72—Manganese
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epoxy Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT omit VIII °nolo III 1101 X1101101 OH Imo oimIE (10) International Publication Number WO 2018/027021 Al (51) International Patent Classification: C07D 303/36 (2006.01) CO1G 45/00 (2006.01) (21) International Application Number: PCT/US2017/045274 (22) International Filing Date: 03 August 2017 (03.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/371,686 05 August 2016 (05.08.2016) US 62/536,862 25 July 2017 (25.07.2017) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Dr., Thousand Oaks, California 91320 (US). (72) Inventors: BEAVER, Matt; 50 Park Avenue, Natick, Massachusetts 01760 (US). CUI, Sheng; 391 Lincoln Street, Lexington, Massachusetts 02421 (US). SHI, Xian- ging; 477 Fallbrook Avenue, Newbury Park, California 91320 (US). (74) Agent: REDDY, G. Prabhakar; One Amgen Center Dr., Thousand Oaks, California 91320 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: — with international search report (Art. 21(3)) (54) Title: SYNTHESIS OF (S)-2-AMINO-4-METHYL-14(R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMA- CEUTICALLY ACCEPTABLE SALTS THEREOF W O 20 18/0 27 0 21 Al (57) : The present invention provides new methods for preparing compound (5), and pharmaceutically acceptable salts thereof, of structure. Compound (5), or a phar- maceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese cat- alyst that may be used in the epoxidation step of the present invention. 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371686P | 2016-08-05 | 2016-08-05 | |
| US201762536862P | 2017-07-25 | 2017-07-25 | |
| PCT/US2017/045274 WO2018027021A1 (en) | 2016-08-05 | 2017-08-03 | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900991UA true SG11201900991UA (en) | 2019-03-28 |
Family
ID=59593230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900991UA SG11201900991UA (en) | 2016-08-05 | 2017-08-03 | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
| SG10201912268UA SG10201912268UA (en) | 2016-08-05 | 2017-08-03 | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912268UA SG10201912268UA (en) | 2016-08-05 | 2017-08-03 | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11708341B2 (en) |
| EP (1) | EP3494108B1 (en) |
| JP (1) | JP7229912B2 (en) |
| KR (1) | KR102482663B1 (en) |
| CN (1) | CN109641863B (en) |
| AU (1) | AU2017306546B2 (en) |
| BR (1) | BR112019002191A2 (en) |
| CA (1) | CA3032963A1 (en) |
| CL (1) | CL2019000294A1 (en) |
| CO (1) | CO2019001139A2 (en) |
| CR (1) | CR20190113A (en) |
| CY (1) | CY1124363T1 (en) |
| DK (1) | DK3494108T3 (en) |
| ES (1) | ES2842575T3 (en) |
| HU (1) | HUE051980T2 (en) |
| IL (1) | IL264549B (en) |
| JO (1) | JOP20190016B1 (en) |
| LT (1) | LT3494108T (en) |
| MX (1) | MX2019001459A (en) |
| PE (1) | PE20190404A1 (en) |
| PH (1) | PH12019500232A1 (en) |
| PL (1) | PL3494108T3 (en) |
| PT (1) | PT3494108T (en) |
| SA (1) | SA519401022B1 (en) |
| SG (2) | SG11201900991UA (en) |
| SI (1) | SI3494108T1 (en) |
| TN (1) | TN2019000028A1 (en) |
| UA (1) | UA125648C2 (en) |
| WO (1) | WO2018027021A1 (en) |
| ZA (1) | ZA201900717B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114195741A (en) * | 2021-12-28 | 2022-03-18 | 南京格亚医药科技有限公司 | Preparation method of carfilzomib key intermediate isomer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| WO2005111009A2 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| JP2006028154A (en) | 2004-06-14 | 2006-02-02 | Sumitomo Chemical Co Ltd | Method for producing optically active compound |
| DK1819353T3 (en) | 2004-12-07 | 2011-05-16 | Proteolix Inc | Composition for proteasome inhibition |
| KR20150131405A (en) | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| EP2349313A4 (en) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones |
| AR087863A1 (en) | 2012-05-08 | 2014-04-23 | Onyx Therapeutics Inc | PROCEDURES FOR THE FORMATION OF CYCLODEXTRINE COMPLEXES TO FORMULATE INHIBITORS OF THE PEPTIDIC PROTEASOME |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| AU2013292636A1 (en) | 2012-07-18 | 2015-02-05 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| DE102013104003B3 (en) | 2013-04-19 | 2014-03-13 | Glatt Systemtechnik Gmbh | Device for introducing a defined amount of a second powder into a process container |
| CN104230857A (en) | 2014-08-19 | 2014-12-24 | 上海皓元生物医药科技有限公司 | Preparation method of intermediate compounds of carfilzomib and intermediate compounds |
-
2017
- 2017-08-03 ES ES17751954T patent/ES2842575T3/en active Active
- 2017-08-03 LT LTEP17751954.3T patent/LT3494108T/en unknown
- 2017-08-03 PL PL17751954T patent/PL3494108T3/en unknown
- 2017-08-03 SG SG11201900991UA patent/SG11201900991UA/en unknown
- 2017-08-03 UA UAA201902137A patent/UA125648C2/en unknown
- 2017-08-03 EP EP17751954.3A patent/EP3494108B1/en active Active
- 2017-08-03 CN CN201780048527.3A patent/CN109641863B/en active Active
- 2017-08-03 CA CA3032963A patent/CA3032963A1/en active Pending
- 2017-08-03 JP JP2019506144A patent/JP7229912B2/en active Active
- 2017-08-03 SG SG10201912268UA patent/SG10201912268UA/en unknown
- 2017-08-03 CR CR20190113A patent/CR20190113A/en unknown
- 2017-08-03 AU AU2017306546A patent/AU2017306546B2/en active Active
- 2017-08-03 JO JOP/2019/0016A patent/JOP20190016B1/en active
- 2017-08-03 SI SI201730575T patent/SI3494108T1/en unknown
- 2017-08-03 TN TNP/2019/000028A patent/TN2019000028A1/en unknown
- 2017-08-03 PE PE2019000337A patent/PE20190404A1/en unknown
- 2017-08-03 HU HUE17751954A patent/HUE051980T2/en unknown
- 2017-08-03 US US16/327,079 patent/US11708341B2/en active Active
- 2017-08-03 PT PT177519543T patent/PT3494108T/en unknown
- 2017-08-03 WO PCT/US2017/045274 patent/WO2018027021A1/en unknown
- 2017-08-03 DK DK17751954.3T patent/DK3494108T3/en active
- 2017-08-03 KR KR1020197006357A patent/KR102482663B1/en active IP Right Grant
- 2017-08-03 MX MX2019001459A patent/MX2019001459A/en unknown
- 2017-08-03 BR BR112019002191-4A patent/BR112019002191A2/en active Search and Examination
-
2019
- 2019-01-30 IL IL264549A patent/IL264549B/en unknown
- 2019-01-31 PH PH12019500232A patent/PH12019500232A1/en unknown
- 2019-02-04 CL CL2019000294A patent/CL2019000294A1/en unknown
- 2019-02-04 SA SA519401022A patent/SA519401022B1/en unknown
- 2019-02-04 ZA ZA2019/00717A patent/ZA201900717B/en unknown
- 2019-02-07 CO CONC2019/0001139A patent/CO2019001139A2/en unknown
-
2021
- 2021-01-27 CY CY20211100067T patent/CY1124363T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201811161YA (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201811311VA (en) | Compounds for imaging tau protein aggregates | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201805494WA (en) | Mutated von willebrand factor |